1. "2019"
Formats
  1. Journal Article (2144)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2450)
  2. Solid Tumor Oncology Division (1408)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (937)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5611)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5611)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Meeting Abstract

    Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H.; Kim, S.; Lin, Z.; Youkstetter, J.; Sen, S.; Cheng, A.; Meyer, T.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
    Meeting Abstract

    Javle, M.; Borbath, I.; Clarke, S.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D.; Spratlin, J.; Valle, J.; Weiss, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Saura, C.; Piha-Paul, S. A.; Lu, J.; Mayer, I. A.; Brufksy, A. M.; Spanggaard, I.; Arnedos, M.; Cutler, R. E.; Hyman, D. M.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Meeting Abstract

    Planchard, D.; Li, B. T.; Murakami, H.; Shiga, R.; Lee, C. C.; Wang, K.; Jänne, P. A.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
    Meeting Abstract

    Shaw, A.; Riely, G. J.; Bang, Y. J.; Kim, D. W.; Camidge, D. R.; Shapiro, G. I.; Usari, T.; Wang, S. C.; Wilner, K.; Clark, J. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • VOYAGER: An open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour
    Meeting Abstract

    Bauer, S.; George, S.; Kang, Y.; Jones, R.; Mir, O.; Tap, W.; Doyle, A.; Picazio, N.; Zhou, T.; Roche, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Reznik, E.; Smith, M. L.; Sebra, R.; Cantley, L. C.; Scaltriti, M.; Baselga, J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion lung cancer
    Meeting Abstract

    Drilon, A.; Kummar, S.; Moreno, V.; Patel, J.; Lassen, U.; Rosen, L.; Childs, B. H.; Nanda, S.; Cox, M. C.; Ku, N. C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: A double-blind, randomized, placebo-controlled phase 3 study
    Meeting Abstract

    Chung, H.; Bang, Y.; Fuchs, C.; Qin, S.; Satoh, T.; Shitara, K.; Tabernero, J.; Van Cutsem, E.; Cao, Z.; Chen, X.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Comparative analyses between younger and older patients with pancreatic adenocarcinoma: Differences in clinicopathological features, treatment patterns, and outcomes
    Meeting Abstract

    Salem, M.; Kadakia, K.; Trufan, S.; Hwang, J.; Nazemzadeh, R.; Jagosky, M.; Worrilow, W.; Coley, H.; Al Hallak, M.; Gower, N.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save